Asia-Pacific CRO Novotech signs MOU with Taiwanese hospital

By Melissa Fassbender contact

- Last updated on GMT

(Image: Getty/utah778)
(Image: Getty/utah778)
Novotech has signed a Memorandum of Understanding (MOU) with the China Medical University Hospital (CMUH) in Taiwan.

The Australia-headquartered contract research organization (CRO) Novotech have five MOUs with major health providers.

Per its agreement with the CMUH, the hospital will provide Novotech’s team with “professional and medical clinical trial advice,”​ including feasibility, principal investigator selection, and patient recruitment support.

Conversely, Novotech will promote CMUH’s clinical research capabilities, specifically its Phase I unit.

The CMUH has 2,054 beds and a dedicated Clinical Trials Center (CTC), which joined the "International Clinical Trials Center Network" (ICN) in 2016.

The ICN includes Zurich University, Harvard University, Cambridge University, and the University of Hong Kong.

Related topics: Clinical Development, Phase I-IV

Related news

Show more

Related products

show more

Next generation ePRO from SQN Health

Next generation ePRO from SQN Health

Syne Qua Non Clinical | 16-May-2018 | Business Advice

In an era of rapid technology growth, healthcare requires low cost solutions for real-time data collection. We have come a long way from paper to EDC and...

Leveraging Best Practices in Primary Packaging

Leveraging Best Practices in Primary Packaging

Catalent Pharma Solutions | 05-Mar-2018 | Technical / White Paper

When planning a clinical trial, overlooking the importance of primary packaging can be a mistake. From stability concerns to labeling to patient compliance...

Related suppliers

Follow us

Featured Events

View more


View more